Acta Med Scand 1982;212(3):115-120
Dose escalation should proceed according to FDA-approved titration schedules, typically every 4 weeks, though individual tolerance may necessitate slower progression
Some pharmaceutical companies offer patient assistance programs, and there may be local resources or charitable organizations that can help with costs
The goal is always the lowest effective dose for each individual, not a specific number
HIF-1 regulates the expression of several genes associated with tumor progression, suggesting that 2-AR may play a role in the proliferation and invasion of liver cancer cells through the HIF-1/VEGFA signaling pathway
The 48 week BELIEVE Phase 2 compared a multiple placebo arm to semaglutide4 (1.0mg or 2.4mg), bimagrumab (10 mg/kg, 30 mg/kg), and sema-bima (1.0mg, 2.4mg semaglutide X 10 mg/kg, 30 mg/kg bimagrumab)